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Introduction: The balance between TH1, TH2, TH17, and regulatory T cells has been suggested 
to be disturbed in type 1 diabetes (T1D). We investigated this balance in peripheral blood 
mononuclear cells (PBMC) from children at risk of developing T1D and children with T1D.
Methods: We studied PBMC expression levels of markers related to TH1 (T-bet, IL-12Rβ1, 
IL-12Rβ2), TH2 (GATA-3, IL-4Rα), TH17 (IL-17A), and regulatory T cells (Foxp3, ICOS, and 
CTLA-4) with real-time polymerase chain reaction from 17 children with T1D, 13 children with 
β-cell autoimmunity, 15 children with T1D risk-associated human leukocyte antigen (HLA) 
haplotypes, and 24 healthy, control children.
Results: We observed decreased expression levels of GATA-3 by PBMC of healthy children 
with autoantibodies compared to healthy, control children (p = 0.014) or children with HLA 
risk alleles (p = 0.032). Children with T1D demonstrated lower expression levels of T-bet, 
IL-12Rβ1, and IL-4Rα both at diagnosis and 12 months later.
Conclusion: We found no indication of aberrant activation of  TH1, TH17, or Treg in peripheral 
blood from children with or without risk of T1D. The observed immunological differences 
between children at risk of and with T1D should be considered when immunopathogenesis of 
β-cell destruction is studied.
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Introduction
The expression proﬁ  le of T-cell transcription factors and cytokine receptors reﬂ  ects the 
activation status of the immune system. The functional arms of the adaptive immune 
system includes T helper (TH)1, TH2, TH17, and regulatory T cells (Treg), and the bal-
ance between these may be aberrant in immune-mediated disease.
Interleukin-12 (IL-12) is a strong promoter of TH1 immune responses and the T cell 
response to IL-12 is dependent on the expression of the high afﬁ  nity IL-12 receptor 
(IL-12R). This receptor consists of β1 and β2 subunits, which are both necessary for 
signal transduction. The IL-12Rβ1 subunit can be detected on resting T-cells, but the 
β2 subunit is induced only upon antigen activation (Szabo et al 1997). Signals via the 
IL-12R upregulate T-bet, a protein primarily expressed in TH1 cells (Szabo et al 2000), 
but also in type 1 cytotoxic T (TC1) cells (Sullivan et al 2003) and dendritic cells 
(Lugo-Villarino et al 2003). In TH cells, T-bet, together with interferon-gamma (IFN-γ), 
forms an autoregulatory positive feedback loop to maintain a TH1 response and inhibit 
IL-5 production (Lametschwandtner et al 2004).
GATA-3 and the IL-4 receptor (IL-4R) are believed to be crucial for the 
development and maintenance of a TH2 phenotype. IL-4R regulates the production Journal of Inﬂ  ammation Research 2008:1 12
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of cytokines such as IL-4, IL-5, and IL-13 through GATA-3 
in TH2 cells (Szabo et al 2003), and a recent study shows that 
Tc2 cells also express GATA-3 (Chen et al 2005).
The ratio between T-bet and GATA-3 expression levels, 
as a measure of TH1 and TH2 immune responses, has been 
implicated in different autoimmune diseases, such as rheu-
matoid arthritis (RA), idiopathic thrombocytopenic purpura 
(ITP), and systemic lupus erythematosus (SLE) (Kawashima 
and Miossec 2005; Wang et al 2005; Chan et al 2006).
A new subset of T cells, distinct from TH1 and TH2, has 
recently been classiﬁ  ed and named TH17. This subset of cells 
develops from naïve T cells in response to IL-23 (Harrington 
et al 2005; Park et al 2005; Wynn 2005) and has the abil-
ity to produce IL-17A, IL-17F, and IL-22 (Aggarwal et al 
2003; Zheng et al 2007), which are potent proinﬂ  ammatory 
cytokines (Kolls and Linden 2004). TH17 cells seem to be 
central in the development of pathogenic tissue destruction 
in multiple sclerosis and rheumatoid arthritis (Kotake et al 
1999; Hwang and Kim 2005; Kebir et al 2007).
Regulatory T cells (Treg) are characterized by expression 
of CD25, CTLA-4, and Foxp3 and play an active role in 
downregulating immune responses. Foxp3 seems to be a key 
factor in the development and function of naturally occurring 
Treg (Hori et al 2003), and decreased Foxp3 mRNA levels 
have been observed in patients with autoimmune diseases 
(Huan et al 2005). Recent studies have, on the other hand, 
shown that Foxp3 is upregulated upon T-cell activation and 
results in hyporesponsiveness of the activated T-cell (Morgan 
et al 2005; Wang et al 2007).
In type 1 diabetes (T1D), a functional imbalance between 
TH1, TH2, and Treg cells has been suggested by several 
research groups, including our own (Rabinovitch et al 1996; 
Shimada et al 1996; Halminen et al 2001; Kukreja et al 2002; 
Faresjo et al 2006), whereas the role of TH17 cells in human 
T1D is not known. Since hyperglycemia, ketoacidosis, or 
insulin treatment may affect immune cells, we studied the 
balance between markers of TH1, TH2, TH17, and Treg cells 
in peripheral blood mononuclear cells (PBMC) from children 
at risk of T1D and diabetic children followed during the ﬁ  rst 
year after diagnosis.
Materials and methods
Subjects
The study includes a total of 69 children. Forty-four 
children participated in the population-based ABIS study 
(All Babies in south-east Sweden) (mean age 5.3 years; 
range 5.0–6.0 years). The ABIS study is a population-based 
follow-up study of all infants born between October 1st, 1997 
and October 1st, 1999, in which newborns have been 
followed prospectively. Among the children participating in 
the ABIS study we selected 15 children (mean age 5.4 years; 
range 5.0–6.0 years) expressing human leukocyte antigen 
(HLA) class II haplotypes associate with an increased risk 
for T1D development (HLA-DR3-DQ2 or HLA-DR4-DQ8), 
without autoantibody production, and 13 children (mean 
age 5.3 years; range 5.1–5.7 years) who were autoantibody 
positive for GADA and/or IA-2A and/or IAA (11 of whom 
also expressed HLA haplotypes associated with increased 
risk for T1D). Antibody levels above the 98th percentile 
for GADA and IAA and the 99th percentile for IA-2 were 
regarded as positive values.
Sixteen ABIS children (mean age 5.3 years; range 
5.0–5.6 years) who did not express the T1D risk-associated 
HLA alleles and were negative for autoantibodies were 
used as healthy controls for the children at risk for T1D 
development.
The T1D patients consisted of 17 children (mean age 
10.4 years; range 6.0–15.6 years) treated at the Pediatric 
Clinic, Linköping University hospital. Children with T1D 
were followed with samples taken ten days, three months 
(range 1–3 months), and one year (range 9–18 months) after 
diagnosis. At the same time points glycosylated hemoglobin 
(HbA1c) values were recorded. Eight children with a mean 
age of 11.7 years (range 11.0–12.8 years) were enrolled 
from a nearby school and used as controls for the diabetic 
children. These children did not have any family members 
with autoimmune disease or allergy and were regarded as 
healthy.
Measurement of autoantibodies
Levels of autoantibodies against glutamic acid decarboxylase 
(GAD), tyrosine phosphatase-like insulinoma antigen 
2 (IA-2) and insulin were analyzed in serum by radiobinding 
assay described previously (Holmberg et al 2006).
In the Diabetes Autoantibody Standardization Program 
(DASP) 2005 for GADA, we observed a speciﬁ  city of 96% 
and sensitivity of 76%, for IA-2A, a speciﬁ  city of 100% and 
sensitivity of 72%, and for IAA, a speciﬁ  city of 100% and 
a sensitivity of 30%.
Results were expressed as concentrations of autoanti-
bodies calculated in relation to a standard curve.
HLA genotyping
HLA genotyping was done using biotinylated primers for 
DQB1, DQA1, or DRB1 genes. The ampliﬁ  ed regions were, 
after denaturation, hybridized with a mix of sequence speciﬁ  c Journal of Inﬂ  ammation Research 2008:1 13
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probes labeled with various lanthanide (europium, samarium, 
and terbium) chelates.
Specific signals for each label were measured by 
time-resolved ﬂ  uorometry after washes and addition of 
enhancement solution. Details of the method, including 
primer and probe sequences, have been described previously 
(Sjoroos et al 1998; Nejentsev et al 1999).
Preparation of samples
Human PBMC were isolated from peripheral blood by 
Ficoll-Paque™ (Amersham Biosciences AB, Uppsala, 
Sweden) density gradient centrifugation and stored in liquid 
nitrogen until further analysis.
Real-time polymerase chain reaction
PBMCs were analyzed for expression of GATA-3, T-bet, 
IL-4Rα, IL-12Rβ1, IL-12β2, IL-17A, Foxp3, ICOS, and 
CTLA-4 using real-time polymerase chain reaction (PCR).
Brieﬂ  y, total ribonucleic acid (RNA) was extracted from 
unstimulated PBMC using the GenElute Mammalian total 
RNA kit® (Sigma, St. Louis, MO, USA). Genomic DNA 
were eliminated by an additional treatment with DNAse 
I (0.01 U/µL) (Roche Diagnostics, Mannheim, Germany), 
after which RNA was converted to complementary DNA 
(cDNA) according to the manufacturer’s protocol, using 
random hexamers and Multiscribe Reverse transcriptase 
(Applied Biosystems, Foster City, CA, USA). Reactions 
were carried out in a total volume of 20 µL.
mRNA expression was determined by the TaqMan 
method of real-time PCR, with ribosomal 18s RNA 
(rRNA) as endogenous control. TaqMan Universal 
PCR master mix with AMPerase UNG and the 
primers and probes for rRNA (cat.no. Hs99999901_s1), 
GATA-3 (cat.no. Hs00231122_m1), T-bet (cat.no. 
Hs00203436_m1), IL-4Rα (cat.no. Hs00166237_m1), 
IL-12Rβ1 (cat.no. Hs00234651_m1), IL-12Rβ2 (cat.no. 
Hs00155486_m1), IL-17A (cat.no. Hs00174383_m1), ICOS 
(cat.no. Hs00359999_m1), CTLA-4 (cat.no. Hs00175480_m1), 
and Foxp3 (cat.no. Hs00203958_m1) were purchased from 
Applied Biosystems.
Each measurement was performed in triplicate with 
1.8 µL of cDNA, except for IL-17A where 18 µL cDNA 
was used. The thermal cycle conditions were set with an 
initial step of 2 min at 50 °C and 10 min at 95 °C, followed 
by 50 cycles of 15 s at 95 °C and 1 min at 60 °C. Water was 
included as no template control (NTC).
The comparative Ct method described by the manu-
facturer is used to calculate a relative transcription value. 
For presentations, the relative amount of target genes was 
multiplied by 100.
Characteristics of subjects
Children participating in the ABIS study had an overall mean 
age of 5.4 years (range 5.0–6.0 years) and included 18 girls 
and 26 boys.
Diabetic children included nine girls and eight boys with 
a mean age of 10.4 years (ranging from 6.0 to 15.6 years). 
At diagnosis, the median value of HbA1c was 10.3% 
(range 8.4–11.7) but improved during follow-up. At three 
months, the median was 5.1% (range 3.9–8.5) and at twelve 
months the median was 6.2% (range 4.7–8.2). Insulin 
requirements were between 0.4 and 1.4 U/kg/24 h at three 
months, and between 0.5–1.7 U/kg/24h at twelve months. 
The eight schoolchildren enrolled as controls included three 
girls and ﬁ  ve boys, with the mean age of 11.7 years (range 
11.0–12.8).
Statistical analysis
Since the levels of mRNA were not normally distributed, non-
parametric tests, corrected for ties, were used. Comparisons 
between unpaired groups were analyzed with Kruskal-Wallis 
as a pretest and Mann-Whitney U test was used for com-
parison of two unrelated groups. Friedman test was used 
for analysis between paired groups and correlations were 
analyzed with Spearman’s rank correlation test.
A p-value below 0.05 was considered signiﬁ  cant without 
corrections for multiple comparisons (Perneger 1998). 
All calculations were performed with the statistical package 
SPSS 14.0 (SPSS Inc., Chicago, IL, USA).
Ethics
Informed consent was obtained from all children and parents, 
and the regional Research Ethics Committee of the Faculty 
of Health Sciences, Linköping approved the study.
Results
Activation stage of peripheral blood 
mononuclear cells in healthy children 
at risk of type 1 diabetes
PBMC of high-risk individuals, deﬁ  ned as children with 
β-cell autoantibodies and HLA risk genotype, demonstrated 
lower expression levels of GATA-3 in PBMC than healthy 
control children (p = 0.014) (see Figure 1) and children 
expressing an HLA risk genotype but without autoantibodies Journal of Inﬂ  ammation Research 2008:1 14
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(p = 0.032). The children with genetic risk alone did not differ 
from the control children without genetic risk.
The amount of IL-17A expressed in PBMC was low 
but using ten times more cDNA, between 77%–88% of the 
individuals in each group had measurable levels but no differ-
ences in IL-17A expression or expression of T-bet, IL-4Rα, 
IL-12Rβ1, IL-12β2, Foxp3, ICOS, and CTLA-4 was found 
between healthy children at risk compared to those without 
risk (data not shown).
Activation stage of peripheral blood 
mononuclear cells in children with T1D
In the PBMC of patients with T1D, mRNA levels of 
IL-12Rβ1 (see Figure 2a) and IL-4Rα (see Figure 2b) 
were lower compared to the healthy control children. This 
difference was observed in samples taken at diagnosis of 
the disease (day 10) as well as in samples taken three and 
12 months following diagnosis. The expression of T-bet (see 
Figure 2c) was also signiﬁ  cantly lower at diagnosis com-
pared to controls, but the same tendency was not observed 
in subsequent samples.
The levels of IL-17A, GATA-3, or IL-12Rβ2 speciﬁ  c 
mRNA did not differ between samples taken from diabetic 
children and healthy controls (data not shown).
Foxp3 expression was lowest in samples taken at 
12 months following diagnosis when it was signifi-
cantly decreased when compared to the healthy control 
group (p = 0.027) (see Figure 3a). At 12 months, the expres-
sion was lower than at diagnosis, and also tended to be 
lower than in samples taken at three months after diagnosis 
(p = 0.038 and p = 0.056, respectively). The expression of 
ICOS or CTLA-4 did not differ between the groups (data 
not shown).
Expression of measured marker did not show signiﬁ  cant 
changes in the T1D children during follow-up using paired 
analysis (data not shown).
The relation of insulin dose, HbA1c,
and autoantibodies to transcription 
factors in diabetic children
At three months of diabetes duration we observed a negative 
correlation between insulin dose per kg body weight, 
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Figure 1 Levels of GATA-3 speciﬁ  c mRNA in PBMC was lower in children with β-cell autoantibodies (Aab+) than control children (Control) and children with HLA risk 
genotype (HLA risk). Two children with autoantibodies but without HLA risk genotype are marked with arrows. Horizontal lines indicate median values and p-values of Mann-
Whitney U-test are shown in the ﬁ  gure.
Abbreviations: HLA, human leukocyte antigen; PBMC, peripheral blood mononuclear cells.Journal of Inﬂ  ammation Research 2008:1 15
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Figure 2 Relative expression level of speciﬁ  c mRNA in PBMC from children with T1D at different duration and in healthy control children. The levels of IL-12Rβ1 mRNA 
(a) (type 1 marker), IL-4Rα mRNA (b) (type 2 marker) was lower at all time points, and T-bet mRNA (c) (type 1 marker) was decreased at diagnosis and after 12 month. 
Horizontal lines indicate median values and p-values of Mann-Whitney U-test are shown in the ﬁ  gure.
Abbreviations: HLA, human leukocyte antigen; PBMC, peripheral blood mononuclear cells; T1D, type 1 diabetes.
Figure 3 (a) Foxp3 mRNA expression (Treg marker) was lower after 12 month (M12) after diagnosis than earlier during the follow-up in children with T1D, and also when compared 
to healthy controls. (b) Relative expression level of Foxp3 mRNA shows a negative correlation with insulin dose (units/kg/24 h) at 3 months (R = −0.541; p = 0.03).Journal of Inﬂ  ammation Research 2008:1 16
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24 hours, and the level of Foxp3 (R = −0.541; p = 0.030) 
(see Figure 3b). We found no significant correlations 
between immune activation stage of PBMC and HbA1c or 
autoantibodies (data not shown).
Discussion
Deviation of T cell responses, including TH1, TH2, and 
TH17 cells together with Treg activity, may contribute to 
the development of a chronic (auto)immune responses, as in 
T1D. We compared the expression of transcription factors, 
as markers for functional T cell subsets, in ex vivo derived 
peripheral PBMC from diabetic and healthy children. As our 
interest was to evaluate ex vivo expression levels of factors 
responsible for T cell differentiation in unstimulated PBMC, 
we were not able to measure secreted cytokines since in 
unstimulated circulating cells, cytokine secretion is low, or 
even undetectable, for most cytokines.
In the group of at-risk individuals, ie, children with 
β-cell autoantibodies, a decreased expression of GATA-3 
in PBMC was the only aberrancy found in comparison to 
healthy age-matched children. Inhibition of GATA-3 seems 
to be more important than increased levels of T-bet for the 
production of IFN-γ (Chakir et al 2003), and thus the low 
levels of GATA-3 could support the development of TH1 
responses that may be capable of destruction of β-cells. 
However, we did not see any difference in expression levels 
of T-bet or IL-12R, and thus this is rather speculative. The 
major ﬁ  nding in individuals positive for β-cell autoantibod-
ies is that unstimulated peripheral blood reﬂ  ects poorly the 
immune aberrancies related to β-cell autoimmunity leading 
to β-cell destruction. This is in agreement with the view 
that T1D is not a systemic autoimmune disease.
In contrast to children at-risk of T1D, diabetic children 
exhibited lower expression levels of T-bet, IL-12Rβ1, and 
IL-4Rα both at diagnosis and 12 months later compared 
to healthy children. These data suggest poor TH1 immune 
activation in peripheral blood from the children with 
recent-onset clinical diabetes and are in good agreement 
with earlier studies showing decreased expression of IFN-γ 
transcripts in peripheral blood of diabetic patients (Halminen 
et al 2001). Altogether, our results indicate that no general 
activation of type 1 immune responses are observed in 
peripheral blood of children with T1D or that of children 
at-risk of T1D, despite the earlier ﬁ  ndings of high IFN-γ 
response to stimulation reported by some studies (Kallmann 
et al 1997).
The expression of IL-17A transcripts in PBMC was low in 
general and required ten times more templates in the PCR for 
IL-17A. This may indicate that the numbers of                                IL-17A positive cells 
or their functional upregulation are not increased in the peripheral 
blood in children with T1D or in risk individuals. If               TH17 cells are 
involved  in  the  pathogenesis  of                          T1D,  their  role  should,  ideally,  be 
studied locally in the population of T cells inﬁ  ltrating the islets.
Foxp3 expression in unstimulated PBMC did not differ 
between healthy and newly diagnosed diabetic children, but 
the Foxp3 expression was decreased 12 months after diabetes 
diagnosis. Our earlier ﬁ  ndings suggest that activation of  Foxp3 
occurs at the time of diagnosis as a response to insulin treatment 
(Tiittanen et al 2006). Interestingly, we observed a negative cor-
relation between insulin dose and the Foxp3 levels at 3 months 
after diagnosis. This could indicate that the activation status 
of Treg cells near diagnosis may control the β-cell destruction 
and thus be related to the insulin dose needed. Since Foxp3 up-
regulation is associated with T cell activation in humans (Wang 
et al 2007), the decrease of Foxp3 expression from diagnosis 
toward 12 months after diagnosis could be a result of fading 
autoimmune attack with ﬁ  nal loss of β-cells.
We observed impaired type 1 responses in children with 
T1D, but this defect was not seen in children at risk of T1D, 
suggesting an immunological shift from prediabetes to diabe-
tes. This raises the question of whether poor T cell activation in 
T1D is secondary to the metabolic disturbances in diabetes or 
whether it is related to the accelerated β-cell destruction seen at 
diagnosis. We did not observe any direct correlations between 
any of the measured markers and HbA1c values, suggesting 
that this aberrancy is not due to long-term hyperglycemia. It 
remains to be elucidated whether a peripheral decrease T cell 
activation is related to the initiation of autoaggressive β-cell 
destruction in the pancreas, when the disease progresses from 
silent autoimmunity towards clinical diabetes.
Our ﬁ  ndings do not support a general activation of TH1 or 
TH17 responsiveness in children at risk of developing T1D or 
in children diagnosed with T1D. Rather, in the latter subject 
group, the data support a global downregulation of Th1, Th2, 
and Th17 responses. It should nevertheless be emphasized 
that the circulating lymphocytes may not always reﬂ  ect the 
inﬁ  ltrating T cells in the target tissue, and thus our results do 
not demonstrate the local changes of insulitis. It is important 
to realize that an immunological shift takes place from pre-
diabetes to manifest T1D, as we and others (Jain et al 2008) 
have demonstrated, and this should be considered when the 
immuno-pathogenesis of β-cell destruction is studied.
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